Sign in

6185 on Hong Kong Stock Exchange

CanSino Biologics

Logo: CanSino Biologics, Public domain, via Wikimedia Commons3

Chinese vaccine company

CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.2 Its shares trade on Hong Kong Stock Exchange under the symbol 6185.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2009Founded1

Compare with another stock.

  • Ticker6185 on Hong Kong Stock Exchange1
  • Industrypharmaceutical industry1
  • HeadquartersTianjin1
  • Founded inTianjin1
  • Websitewww.cansinotech.com

See how the biggest companies compare on our leaderboards

CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.2

The story

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.

In July 2018, it filed an application to list on the Hong Kong Stock Exchange. It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017. In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).

From Wikipedia’s article on CanSino Biologics, shared under CC BY-SA 4.0.4

Timeline

  1. Mar 28, 2019Went public Listed on Hong Kong Stock Exchange1
  2. 2009Founded Founded in Tianjin1

Calendar

Drug trials and FDA: coming up

  1. Oct 2026Phase 1/2 trial readout expected Phase 1/2 trial of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose and others in Poliomyelitis: primary completion expected Oct 2026 (ClinicalTrials.gov NCT06577298).5
  2. Nov 24, 2026Phase 1/2 trial readout expected Phase 1/2 trial of 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H) and others in Streptococcus Pneumoniae Infection: primary completion expected Nov 24, 2026 (ClinicalTrials.gov NCT07600983).6
  3. Feb 15, 2027Phase 3 trial readout expected Phase 3 trial of PCV13i and Prevnar 13 in Pneumococcal Infections: primary completion expected Feb 15, 2027 (ClinicalTrials.gov NCT07017777).7

Drug trials and FDA: recently

  1. Apr 10, 2026Phase 4 trial completed Phase 4 trial of MCV4 in Epidemic Meningitis: primary completion Apr 10, 2026, no results posted yet (ClinicalTrials.gov NCT06389513).8

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8